A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT ID: NCT06574568
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
70 participants
INTERVENTIONAL
2024-06-14
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
NCT05740891
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NCT05739188
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NCT05749133
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06581640
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06655519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
YKST02
Participants will receive different doses of YKST02 in 21-day cycles via intravenous injection.
YKST02
BCMA-CD3 bispecific antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YKST02
BCMA-CD3 bispecific antibody
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of multiple myeloma according to the IMWG criteria.
3. Receipt of at least two prior classes of drugs either in separate regimens or as combinations. The three classes are defined as: An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.
4. Measurable disease at screening, as defined by at least 1 of the following:
1. Serum M-protein ≥0.5 g/dL;
2. Urinary M-protein excretion ≥200 mg/24 hours;
3. Abnormal serum free light chain (FLC) ratio ( \<0.26 or \>1.65) and serum immunoglobulin FLC≥10 mg/dL.
5. Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-1.
6. An estimated survival time of more than 12 weeks.
7. Recovery to Grade 0-1 (Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0) from adverse events related to prior therapy except alopecia.
8. Adequate hematological and organ function.
9. Female participants of childbearing potential must have a negative serum pregnancy test at screening. Female patients who are sexually active must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.
10. Male participants must agree to use reliable methods of contraception (barrier methods or sexual abstinence) and avoid sperm donation throughout the study period and until 3 months after the last dose.
Exclusion Criteria
2. History of antitumor therapy as follows, before the first dose of study drug:
1. Targeted therapy with small molecule drug within 2 weeks or 5 half-lives, whichever is longer;
2. Targeted therapy with macromolecular drug or Immunomodulatory agent therapy within 2 weeks;
3. Chemotherapy within 2 weeks;
4. Treatment with an investigational drug within 2 weeks or 5 half-lives, whichever is shorter;
5. Radical/extensive radiotherapy within 4 weeks, or local palliative radiotherapy within 2 weeks, or acute toxicity induced by previous radiotherapy have not recovered to grade ≤1;
6. Autologous stem cell transplantation within 12 weeks;
7. History of organ transplant, or allogeneic stem cell transplantation within 6 months;
8. Prior treatment with any B cell maturation antigen (BCMA) targeted therapy;
9. Prior treatment with any BCMA targeted chimeric antigen receptor modified \[CAR\]-T cells therapy.
3. Any active acute graft-versus-host disease (GvHD), grade 2-4 (according to Glucksberg criteria) or active chronic GvHD requiring systemic treatment within 2 weeks.
4. Prior myelodysplastic syndrome or malignancy within 5 years, except for localized malignancies that have been adequately treated or free of the disease for ≥ 5 years, e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-muscle invasive bladder cancer, localized prostate cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast.
5. Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma, or other evidence of uncontrolled metastases to the CNS or meninges, judged by the investigator.
6. (a) History of or current relevant CNS pathology as epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis; (b) Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI.
7. History or evidence of cardiovascular disease, including:
1. Acute coronary syndromes (eg, myocardial infarction, unstable angina) within 6 months prior to enrollment;
2. Coronary angioplasty or stenting within 6 months prior to enrollment;
3. Clinically significant unstable arrhythmias (eg, atrial fibrillation), however, atrial fibrillation has been controlled for over 30 days prior to the first dose of YKST02 were allowed;
4. New York Heart Association (NYHA) stage III or higher congestive heart failure within 6 months prior to enrollment; Cardiac valve morphological abnormalities recorded by ECHO (≥ grade 2), note that grade 1 cardiac valve morphological abnormalities (such as mild regurgitation/stenosis) were allowed, but participants with moderate valve thickening were excluded;
5. Left ventricular ejection fraction (LVEF) below lower limit of the study center, or LVEF\<50% if there is no lower limit at the study center;
6. The Fridericia-corrected QT interval (QTcF) ≥ 470 msec (female) or ≥ 450 msec (male)；
7. Implantable defibrillator;
8. Clinically uncontrollable hypertension (i.e., SBP≥160 mm Hg and/or DBP≥100 mm Hg).
8. Known allergy to monoclonal antibody drugs or exogenous immunoglobulin.
9. Any major organ surgery or significant trauma within 4 weeks prior to the first dose of YKST02, or those requiring elective surgeries during the study, and all AEs associated with surgery or significant trauma have not recovered before the first dose of the YKST02.
10. Regular dose of systemic corticosteroids during 4 weeks prior to initiation of study drug, or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent during the trial, or any other systemic immunosuppressive therapy within 4 weeks prior to study entry.
11. Virological tests: Hepatitis B virus surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) quantitative \>ULN of the testing institution; Hepatitis C antibody (HCV-Ab) positive and hepatitis C virus-RNA (HCV-RNA) quantitative \> ULN of the testing institution; Anti-human immunodeficiency virus (Anti-HIV) positive. Participants will be excluded from the study if any of the above criteria is met.
12. Uncontrolled active infections requiring oral or intravenous systemic therapy, except for local treatment.
13. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently).
14. Pregnant or lactating women.
15. Known mental disorder that may affect study compliance or poor compliance.
16. Receipt of any live attenuated vaccines or live virus vaccine within 4 weeks prior to the first dose of study treatment.
17. Other serious systemic diseases or laboratory abnormalities or other reasons that the investigator believes are not appropriate for participating the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Excyte Biopharma Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wenming Chen, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Chao Yang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Jishuitan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Shunde Hospital of Southern Medical University
Foshan, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
Shanxi Cancer hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Li Bao
Role: primary
Lan Deng, MD
Role: primary
Zhongjun Xia
Role: primary
Jie Xiao
Role: primary
Xiaohong Tan, MD
Role: primary
Aichun Liu
Role: primary
Baijun Fang, MD
Role: primary
Meiyun Fang
Role: primary
Xiang Li
Role: backup
Lijie Xing
Role: primary
Qi Dang, MM
Role: backup
Liping Su, MD
Role: primary
Jie Jin, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YKST02-I-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.